Parsons Capital Management Inc. RI Sells 2,050 Shares of Sanofi (NASDAQ:SNY)
Parsons Capital Management Inc. RI cut its position in shares of Sanofi (NASDAQ:SNY) by 5.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,685 shares of the company’s stock after selling 2,050 shares during the period. Parsons Capital Management Inc. RI’s holdings in Sanofi were worth $1,617,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Cardinal Capital Management Inc. acquired a new position in shares of Sanofi during the first quarter valued at $25,000. Reby Advisors LLC bought a new position in Sanofi in the fourth quarter valued at approximately $35,000. Arkadios Wealth Advisors acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $36,000. Charter Oak Capital Management LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $40,000. Finally, JJJ Advisors Inc. lifted its position in shares of Sanofi by 193.8% in the fourth quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock valued at $41,000 after buying an additional 562 shares during the last quarter. Hedge funds and other institutional investors own 6.93% of the company’s stock.
A number of analysts have recently issued reports on SNY shares. Barclays reaffirmed an “equal weight” rating on shares of Sanofi in a research report on Thursday, April 29th. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, February 10th. UBS Group reaffirmed a “buy” rating on shares of Sanofi in a report on Tuesday, January 19th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Sanofi in a report on Friday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $53.00.
Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Wednesday, April 28th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.83 by $0.14. Sanofi had a return on equity of 24.77% and a net margin of 14.49%. The company had revenue of $8.59 billion for the quarter, compared to analyst estimates of $8.48 billion. During the same quarter last year, the company posted $1.63 EPS. The company’s revenue for the quarter was down 4.3% compared to the same quarter last year. As a group, research analysts forecast that Sanofi will post 3.49 EPS for the current fiscal year.
The firm also recently declared an annual dividend, which will be paid on Wednesday, May 26th. Stockholders of record on Tuesday, May 4th will be paid a $1.9061 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.21. The ex-dividend date of this dividend is Monday, May 3rd. This represents a dividend yield of 3.2%. Sanofi’s dividend payout ratio (DPR) is presently 35.24%.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Recommended Story: ESG Score
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.